tellurium and Adenocarcinoma

tellurium has been researched along with Adenocarcinoma* in 2 studies

Other Studies

2 other study(ies) available for tellurium and Adenocarcinoma

ArticleYear
Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    International journal of pharmaceutics, 2016, Mar-16, Volume: 500, Issue:1-2

    In this study, we report the design and delivery of tumor-targeted, quantum dot (QD) and doxorubicin (DOX)-encapsulated PEG-PLGA nanopolymersomes (NPs) for the imaging and chemotherapy of breast cancer. To achieve active cancer targeting, QD and DOX-encapsulated NPs were conjugated with folate for folate-binding protein receptor-guided delivery, which overexpressed in many cancer cells. Hydrophobic DOX and hydrophilic MSA-capped QD were encapsulated in the bilayer and core of the PEG-PLGA nanopolymersomes, respectively. The data show that the formulated NPs sustained DOX release for a period of 12 days. Fluorescence microscopy and MTT assay demonstrated that the developed folate-targeted DOX-QD NPs had higher cytotoxicity than non-targeted NPs and the free form of the drug; moreover, they preferentially accumulated in 4T1 and MCF-7 cells in vitro. In vivo experiments including whole organ tissue-homogenate analysis and organ fluorescence microscopy imaging of BALB/c mice bearing 4T1 breast adenocarcinoma showed that the folate receptor-targeted QD encapsulated NPs accumulate at tumor sites 6h following intravenous injection. Acute toxicity studies of the prepared targeted QD-loaded NPs showed no evidence of long-term harmful histopathological and physiological effects on the treated animals. The in vivo tumor inhibitory effect of folic acid (FA)-QD-DOX NPs demonstrated an augmented therapeutic efficacy of targeted formulation over the non-targeted and free drug. The data obtained illustrate a high potential of the prepared targeted theranostic nanoplatform in the treatment and imaging of breast cancer. This study may open new directions for preparation of QD-based theranostic polymersomes for clinical application.

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cadmium Compounds; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Drug Liberation; Folic Acid; Folic Acid Transporters; Humans; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; NIH 3T3 Cells; Polyesters; Polyethylene Glycols; Quantum Dots; Tellurium; Tumor Burden

2016
Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift.
    Free radical biology & medicine, 2009, Sep-15, Volume: 47, Issue:6

    Selenium is an essential trace element incorporated as selenocysteine in 25 human selenoproteins. Among them are thioredoxin reductases (TrxR) and glutathione peroxidases, all central proteins in the regulation of the cellular thiol redox state. In this paper the effects of selenite and tellurite treatment in human cancer cells are reported and compared. Our results show that both selenite and tellurite, at relatively low concentrations, are able to increase the expression of mitochondrial and cytosolic TrxR in cisplatin-sensitive (2008) and -resistant (C13*) phenotypes. We further investigated the cellular effects induced by selenite or tellurite in combination with the specific TrxR inhibitor auranofin. Selenite pretreatment induced a dramatic increase in auranofin cytotoxicity in both resistant and sensitive cells. Investigation of TrxR activity and expression levels as well as the cellular redox state demonstrated the involvement of TrxR inhibition and redox changes in selenite and auranofin combined action.

    Topics: Adenocarcinoma; Auranofin; Cell Death; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Ovarian Neoplasms; Sodium Selenite; Tellurium; Thioredoxin-Disulfide Reductase

2009